MCID: FBR017
MIFTS: 57

Fibrosarcoma

Categories: Bone diseases, Cancer diseases, Rare diseases

Aliases & Classifications for Fibrosarcoma

MalaCards integrated aliases for Fibrosarcoma:

Name: Fibrosarcoma 12 75 53 59 29 55 44 15 17 72
Neoplasms, Fibrous Tissue 44 72
Fibrosarcoma of Soft Tissue 12
Fibrous Tissue Neoplasm 12
Fibrocytic Tumor 12

Characteristics:

Orphanet epidemiological data:

59
fibrosarcoma
Prevalence: <1/1000000 (Europe); Age of onset: All ages;

Classifications:

Orphanet: 59  
Rare bone diseases


External Ids:

Disease Ontology 12 DOID:3355
SNOMED-CT 68 53654007
MESH via Orphanet 45 D005354
ICD10 via Orphanet 34 C49.9
UMLS via Orphanet 73 C0016057
Orphanet 59 ORPHA2030
UMLS 72 C0016057 C0206643 C1336021

Summaries for Fibrosarcoma

Disease Ontology : 12 A connective tissue cancer that has material basis in fibrous connective tissue and characterized by the presence of immature proliferating fibroblasts or undifferentiated anaplastic spindle cells in a storiform pattern.

MalaCards based summary : Fibrosarcoma, also known as neoplasms, fibrous tissue, is related to congenital fibrosarcoma and fasciitis. An important gene associated with Fibrosarcoma is ETV6 (ETS Variant Transcription Factor 6), and among its related pathways/superpathways are Degradation of the extracellular matrix and Proteoglycans in cancer. The drugs Cyclophosphamide and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and t cells, and related phenotypes are growth/size/body region and cardiovascular system

Wikipedia : 75 Fibrosarcoma (fibroblastic sarcoma) is a malignant mesenchymal tumour derived from fibrous connective... more...

Related Diseases for Fibrosarcoma

Diseases in the Fibrosarcoma family:

Adult Fibrosarcoma Congenital Fibrosarcoma

Diseases related to Fibrosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 510)
# Related Disease Score Top Affiliating Genes
1 congenital fibrosarcoma 34.8 NTRK3 ETV6 ACTC1
2 fasciitis 31.2 TNF ETV6 ACTC1
3 breast adenocarcinoma 30.9 TNF PLAU MMP9 MMP2
4 rheumatoid arthritis 30.8 TNF TIMP1 MMP9 MALAT1 JUN
5 cellular congenital mesoblastic nephroma 30.6 NTRK3 ETV6
6 aortic aneurysm, familial abdominal, 1 30.6 TIMP2 TIMP1 PLAU MMP9 MMP2
7 calcifying aponeurotic fibroma 30.5 FN1 ACTC1
8 varicose veins 30.4 TIMP2 TIMP1 MMP9 MMP2
9 periodontitis 30.4 TNF TIMP1 MMP9 MMP2
10 ewing sarcoma 30.3 TNF SERPINE1 MMP9 MMP2 JUN
11 lung cancer susceptibility 3 29.7 PLAU MMP9 MMP2 MALAT1 JUN
12 myeloma, multiple 29.5 TNF MALAT1 MAFB MAF FN1
13 breast cancer 28.8 TNF TIMP2 TIMP1 SERPINE1 PLAU NTRK3
14 colorectal cancer 28.8 TNF TIMP2 TIMP1 PLAU MMP9 MMP2
15 ovarian cancer 28.8 TNF TIMP2 PLAU MMP9 MMP2 MMP14
16 liver fibrosarcoma 12.5
17 small bowel fibrosarcoma 12.5
18 breast fibrosarcoma 12.4
19 kidney fibrosarcoma 12.4
20 heart fibrosarcoma 12.4
21 fibrosarcoma of bone 12.4
22 adult fibrosarcoma 12.4
23 conventional fibrosarcoma 12.4
24 central nervous system fibrosarcoma 12.3
25 pediatric fibrosarcoma 12.2
26 diaphyseal medullary stenosis with malignant fibrous histiocytoma 11.8
27 dermatofibrosarcoma protuberans 11.8
28 fibroma 11.6
29 infantile myofibromatosis 11.6
30 desmoid tumor 11.5
31 inflammatory myofibroblastic tumor 11.5
32 chromosome 17q11.2 deletion syndrome 11.2
33 extracranial arteriovenous malformation 10.9 MMP9 MMP2
34 adult mesoblastic nephroma 10.9 NTRK3 ETV6
35 focal myositis 10.9 MMP9 MMP2
36 lentigo maligna melanoma 10.8 MMP9 MMP2
37 amaurosis fugax 10.8 SERPINE1 MMP9
38 spastic entropion 10.8 MMP9 MMP2
39 ischemic colitis 10.8 SERPINE1 MMP9 MMP2
40 conjunctival nevus 10.8 TIMP1 MMP9 MMP2
41 multicentric osteolysis, nodulosis, and arthropathy 10.7 MMP2 MMP14
42 chronic venous insufficiency 10.7 TIMP1 SERPINE1 MMP9
43 osteoarthritis 10.7
44 venous insufficiency 10.7 TIMP1 SERPINE1 MMP9
45 maxillary cancer 10.7 TIMP1 PLAU MMP2
46 psammomatous meningioma 10.7 MMP9 MMP2
47 winchester syndrome 10.7 MMP2 MMP14
48 villous adenocarcinoma 10.7 MMP9 MMP2 FN1
49 monoclonal gammopathy of uncertain significance 10.7 TNF MAFB MAF
50 autoimmune inner ear disease 10.7 TNF TIMP1 MMP9

Graphical network of the top 20 diseases related to Fibrosarcoma:



Diseases related to Fibrosarcoma

Symptoms & Phenotypes for Fibrosarcoma

MGI Mouse Phenotypes related to Fibrosarcoma:

46 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.45 ACTC1 ETV6 FN1 GPI JUN MAF
2 cardiovascular system MP:0005385 10.44 ACTC1 ETV6 FN1 GPI JUN MAFB
3 homeostasis/metabolism MP:0005376 10.43 ACTC1 ETV6 FN1 GPI JUN MAF
4 immune system MP:0005387 10.39 ETV6 FN1 GPI JUN MAF MAFB
5 mortality/aging MP:0010768 10.38 ACTC1 ETV6 FN1 GPI JUN MAF
6 hematopoietic system MP:0005397 10.35 ETV6 FN1 GPI JUN MAFK MMP14
7 nervous system MP:0003631 10.18 FN1 JUN MAF MAFB MAFK MMP14
8 integument MP:0010771 10.15 ETV6 FN1 JUN MAF MMP14 MMP9
9 craniofacial MP:0005382 10.1 FN1 MAF MAFB MMP14 MMP2 PLAU
10 muscle MP:0005369 10.06 ACTC1 FN1 MAFK MMP14 MMP2 MMP9
11 normal MP:0002873 10.06 ACTC1 ETV6 FN1 JUN MAFA MAFB
12 neoplasm MP:0002006 10.03 ETV6 FN1 MMP2 MMP9 PLAU SERPINE1
13 no phenotypic analysis MP:0003012 9.91 ETV6 GPI JUN MAFA MMP14 NTRK3
14 reproductive system MP:0005389 9.91 FN1 MAFB MAFK MMP14 MMP9 NTRK3
15 respiratory system MP:0005388 9.9 GPI JUN MAFB MMP14 MMP2 MMP9
16 skeleton MP:0005390 9.61 FN1 JUN MAFB MMP14 MMP2 MMP9
17 vision/eye MP:0005391 9.23 JUN MAF MMP14 MMP2 MMP9 NTRK3

Drugs & Therapeutics for Fibrosarcoma

Drugs for Fibrosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 129)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
2
Ifosfamide Approved Phase 3 3778-73-2 3690
3
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
4
Etoposide Approved Phase 3 33419-42-0 36462
5
Lenograstim Approved, Investigational Phase 3 135968-09-1
6
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
7
Mechlorethamine Approved, Investigational Phase 2, Phase 3 51-75-2 4033
8
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
9
Epirubicin Approved Phase 3 56420-45-2 41867
10
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
11
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
12
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
13
Histamine Approved, Investigational Phase 3 51-45-6 774
14
Cyproheptadine Approved Phase 3 129-03-3 2913
15 Antirheumatic Agents Phase 3
16 Tubulin Modulators Phase 3
17 Antineoplastic Agents, Phytogenic Phase 3
18 Nucleic Acid Synthesis Inhibitors Phase 3
19
Isophosphamide mustard Phase 3 0
20 Antimitotic Agents Phase 3
21 Etoposide phosphate Phase 3
22 Alkylating Agents Phase 2, Phase 3
23
Liposomal doxorubicin Phase 2, Phase 3 31703
24 Anti-Bacterial Agents Phase 2, Phase 3
25 Antibiotics, Antitubercular Phase 2, Phase 3
26 Topoisomerase Inhibitors Phase 2, Phase 3
27 Antineoplastic Agents, Alkylating Phase 2, Phase 3
28 Gastrointestinal Agents Phase 3
29 Neurotransmitter Agents Phase 3
30 Anti-Allergic Agents Phase 3
31 Serotonin Antagonists Phase 3
32 Histamine H1 Antagonists Phase 3
33 Histamine Antagonists Phase 3
34 Dermatologic Agents Phase 3
35 Serotonin Agents Phase 3
36
Histamine Phosphate Phase 3 51-74-1 65513
37 Antipruritics Phase 3
38
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
39
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
40
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
41
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
42
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
43
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
44
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
45
Bevacizumab Approved, Investigational Phase 2 216974-75-3
46
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60700
47
Sirolimus Approved, Investigational Phase 2 53123-88-9 6436030 5284616 46835353
48
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
49
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
50
Vinorelbine Approved, Investigational Phase 1, Phase 2 71486-22-1 60780 44424639

Interventional clinical trials:

(show top 50) (show all 89)
# Name Status NCT ID Phase Drugs
1 A Phase III Randomized Study of Preoperative Radiotherapy Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcoma (RPS) Unknown status NCT01344018 Phase 3
2 Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
3 Phase III Study of The Role of Barrier Resection in Local Control in Treatment of Extremity Soft Tissue Sarcomas Unknown status NCT02120768 Phase 3
4 Randomised Trial of Post-Operative Radiotherapy Given to Adult Patients With Extremity Soft Tissue Sarcoma [VORTEX] Completed NCT00423618 Phase 3
5 A Phase III Randomized Study of Preoperative Radiation Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcomas (RPS) Completed NCT00091351 Phase 3
6 Randomised Trial Of Single Agent Doxorubicin Versus Doxorubicin Plus Ifosfamide In The First Line Treatment Of Advanced Or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
7 Randomized Phase III Trial of Two Investigational Schedules of Ifosfamide vs. Standard Dose Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
8 Randomized Study Comparing Neoadjuvant Chemotherapy Etoposide + Ifosfamide + Adriamycin (EIA) Combined With Regional Hyperthermia (RHT) Versus Neoadjuvant Chemotherapy Alone in the Treatment of High-Risk Soft Tissue Sarcomas in Adults Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
9 METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP) Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
10 RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
11 MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
12 Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754) Completed NCT02180867 Phase 2, Phase 3 Doxorubicin;Doxorubicin Hydrochloride;Ifosfamide;Pazopanib;Pazopanib Hydrochloride
13 Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
14 TRUSTS: A Phase IIB/III Multicenter Study Comparing the Efficacy of TRabectedin Administered as a 3-Hour or 24-Hour Infusion to Doxorubicin in Patients With Advanced or Metastatic Untreated Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
15 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
16 Phase II Study on Axitinib in Advanced VEGFR and/or PDGFR Solitary Fibrous Tumor Unknown status NCT02261207 Phase 2 Axitinib
17 A Phase II Open-Label Trial of Pazopanib Administered as a Single Agent in Patients With Unresectable or Metastatic Solitary Fibrous Tumor (SFT) and Extraskeletal Myxoid Chondrosarcoma (EMC) Unknown status NCT02066285 Phase 2 Pazopanib
18 Non-randomized Single-center Study Phase II Evaluating the Efficacy and Toxicity of Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma Unknown status NCT01883518 Phase 1, Phase 2
19 Randomized Phase II Study of Brostallicin (PNU-166196A) Versus Doxorubicin as First Line Chemotherapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
20 Phase II Evaluation of Temodal (Temozolomide, Schering) in Previously Treated Advanced Sarcomas Unknown status NCT00003718 Phase 2 temozolomide
21 A Phase I/ II Clinical Trial of MDV9300 (Pidilizumab) in Diffuse Intrinsic Pontine Glioma Unknown status NCT01952769 Phase 1, Phase 2
22 Phase II Open-Label Study of Sunitinib Malate (SU011248) in Adult Patients With Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2 Sunitinib Malate (SU011248)
23 A Phase 2 Study of AZD0530 in Recurrent or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
24 A Phase II Study of Imatinib (NSC-716051) in Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans Completed NCT00084630 Phase 2 imatinib mesylate
25 A Phase 2 Study of Intravenous REOLYSIN® (Wild-Type Reovirus) in the Treatment of Patients With Bone and Soft Tissue Sarcomas Metastatic to the Lung Completed NCT00503295 Phase 2
26 A Phase II Study of Single Agent Depsipeptide (FK228) in Metastatic or Unresectable Soft Tissue Sarcomas Completed NCT00112463 Phase 2 romidepsin
27 Phase II Study on ET-743 in Advanced Soft Tissue Sarcomas of the Adult Completed NCT00003939 Phase 2 trabectedin
28 Exatecan As Second-Line Treatment In Advanced Adult Soft Tissue Sarcoma: A Phase II - Study Of The EORTC Soft Tissue And Bone Sarcoma Group Completed NCT00041236 Phase 2 exatecan mesylate
29 Myeloablative Chemotherapy With Stem Cell Rescue for Rare Poor-Prognosis Cancers Completed NCT00141765 Phase 2
30 Phase II Trial of Gleevec (Formerly Known as STI571) in Patients With Soft Tissue and Bone Sarcomas: A Multi-Disciplinary Trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society Completed NCT00031915 Phase 2 imatinib mesylate
31 Phase II Study of Glivec (Imatinib) in Locally Advanced and/or Metastatic Soft Tissue Sarcomas Expressing the t(17;22)(q22;q13) Translocation Resulting in a COL1A1/PDGF-beta Fusion Protein i.e. DermatoFibroSarcoma Protuberans (DFSP) and Giant Cell Fibroblastoma (GCF) Completed NCT00085475 Phase 2 imatinib mesylate
32 A Phase II Study of Intravenous TZT-1027, Administered Weekly Times Two, Every Three Weeks, to Patients With Advanced or Metastatic Soft Tissue Sarcomas (STS) With Prior Exposure to Anthracycline-Based Chemotherapy Completed NCT00064220 Phase 2 soblidotin
33 A Phase II Study Of Perifosine (D-21266) In Patients With Previously Untreated Metastatic Or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
34 Efficacy And Safety Study Of Brostallicin In Patients With Locally Advanced Or Metastatic Soft Tissue Sarcoma Failing One Prior Chemotherapy Treatment Completed NCT00041249 Phase 2 brostallicin
35 A Phase 1/2, Multicenter, Open-label, Dose-finding Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent or Refractory Solid Tumors. Completed NCT01962103 Phase 1, Phase 2 nab-paclitaxel;nab-paclitaxel
36 A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
37 A Phase II Study of Neoadjuvant Bevacizumab and Radiation Therapy for Resectable Soft Tissue Sarcomas Completed NCT00356031 Phase 2 Bevacizumab
38 Dose Finding and Phase II Study of STI 571 in Advanced Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
39 Myeloablative Chemotherapy With Bone Marrow Rescue For Rare Poor-Prognosis Cancers Completed NCT00002515 Phase 2 carboplatin;thiotepa;topotecan hydrochloride
40 A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors Completed NCT01614795 Phase 2 Temsirolimus
41 Multicenter Parallel Phase II Trial of BI 2536 Administered as One Hour IV Infusion Every 3 Weeks in Defined Cohorts of Patients With Various Solid Tumors. A New Drug Screening Program of the EORTC Network of Core Institutions (NOCI) Completed NCT00526149 Phase 2 BI 2536
42 A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
43 A Phase I/II Study of Paclitaxel, Estramustine Phosphate, and Vinorelbine (PaclEVin) Completed NCT00004105 Phase 1, Phase 2 estramustine phosphate sodium;paclitaxel;vinorelbine ditartrate
44 A Phase II Study of BAY 43-9006 (Sorafenib) in Combination With Cetuximab (Erbitux ) in EGFR Expressing Metastatic Colorectal Cancer (CRC) Completed NCT00326495 Phase 2 Cetuximab;BAY 43-9006
45 Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006), an Oral Vascular Endothelial Growth Factor (VEGF), Rapidly Accelerated Fibrosarcoma (RAF) and FMS-like Tyrosine Kinase 3 (FLT3), in Patients With High-risk MDS and AML Completed NCT00542971 Phase 1, Phase 2 Idarubicin;Sorafenib;Ara-C
46 Solitary Fibrous Tumor: Phase II Study on Trabectedin Versus Adriamycin Plus Dacarbazine in Advanced Patients Recruiting NCT03023124 Phase 2 Trabectedin;Adriamycin;Dacarbazine
47 ERibulin in Advanced Solitary Fibrous Tumor, an ItaliaN Sarcoma Group Phase II Study (ERASING) Recruiting NCT03840772 Phase 2 Eribulin
48 A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors Recruiting NCT03899792 Phase 1, Phase 2 LOXO-292
49 A Non-Inferiority Study of Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin
50 SU2C-SARC032: A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity Recruiting NCT03092323 Phase 2 Pembrolizumab

Search NIH Clinical Center for Fibrosarcoma

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Dacarbazine

Cochrane evidence based reviews: fibrosarcoma

Genetic Tests for Fibrosarcoma

Genetic tests related to Fibrosarcoma:

# Genetic test Affiliating Genes
1 Fibrosarcoma 29

Anatomical Context for Fibrosarcoma

MalaCards organs/tissues related to Fibrosarcoma:

41
Bone, Lung, T Cells, Breast, Endothelial, Liver, Skin

Publications for Fibrosarcoma

Articles related to Fibrosarcoma:

(show top 50) (show all 9556)
# Title Authors PMID Year
1
Biosynthesis and recovery of selenium nanoparticles and the effects on matrix metalloproteinase-2 expression. 9 38
20408816 2010
2
Inhibition of histone deacetylase attenuates hypoxia-induced migration and invasion of cancer cells via the restoration of RECK expression. 9 38
20442303 2010
3
TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo. 9 38
20406839 2010
4
The human alpha11 integrin promoter drives fibroblast-restricted expression in vivo and is regulated by TGF-beta1 in a Smad- and Sp1-dependent manner. 9 38
19913614 2010
5
The benzoylurea derivative F13 inhibits cell growth, migration and invasion through inducing expression of ERK1/2-mediated RECK in fibrosarcoma HT-1080 cells. 9 38
20051826 2010
6
The role of MT2-MMP in cancer progression. 9 38
20117087 2010
7
Timp-2 binding with cellular MT1-MMP stimulates invasion-promoting MEK/ERK signaling in cancer cells. 9 38
19551841 2010
8
Frequent deletion of CDKN2A and recurrent coamplification of KIT, PDGFRA, and KDR in fibrosarcoma of bone--an array comparative genomic hybridization study. 9 38
19862822 2010
9
Inhibition of the expression on MMP-2, 9 and morphological changes via human fibrosarcoma cell line by 6,6'-bieckol from marine alga Ecklonia cava. 9 38
20132738 2010
10
Regulation of homotypic cell-cell adhesion by branched N-glycosylation of N-cadherin extracellular EC2 and EC3 domains. 9 38
19846557 2009
11
Identification of membrane-type 1 matrix metalloproteinase tyrosine phosphorylation in association with neuroblastoma progression. 9 38
19961596 2009
12
VAMP3, syntaxin-13 and SNAP23 are involved in secretion of matrix metalloproteinases, degradation of the extracellular matrix and cell invasion. 9 38
19910495 2009
13
Insulin but not glucagon gene is silenced in human pancreas-derived mesenchymal stem cells. 9 38
19785038 2009
14
[Mechanism of endothelial Rho/Rho kinase in extravascular migration of fibrosarcoma cell]. 9 38
19968078 2009
15
Stabilization of anaphase midzone microtubules is regulated by Rho during cytokinesis in human fibrosarcoma cells. 9 38
19576212 2009
16
bFGF induces changes in hyaluronan synthase and hyaluronidase isoform expression and modulates the migration capacity of fibrosarcoma cells. 9 38
19577615 2009
17
PI3K/Akt activity has variable cell-specific effects on expression of HIF target genes, CA9 and VEGF, in human cancer cell lines. 9 38
19342157 2009
18
Identification of integrins alpha6 and beta7 as c-Jun- and transformation-relevant genes in highly invasive fibrosarcoma cells. 9 38
19405119 2009
19
Paeonol exerts anti-angiogenic and anti-metastatic activities through downmodulation of Akt activation and inactivation of matrix metalloproteinases. 9 38
19571375 2009
20
Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence. 9 38
19478560 2009
21
LC3-mediated fibronectin mRNA translation induces fibrosarcoma growth by increasing connective tissue growth factor. 9 38
19366727 2009
22
A novel mode of cell detachment from fibrillar fibronectin matrix under shear. 9 38
19401337 2009
23
The inhibitory mechanism of a novel cationic glucosamine derivative against MMP-2 and MMP-9 expressions. 9 38
19375915 2009
24
Autotaxin promotes the expression of matrix metalloproteinase-3 via activation of the MAPK cascade in human fibrosarcoma HT-1080 cells. 9 38
19212832 2009
25
Involvement of Rac and Rho signaling in cancer cell motility in 3D substrates. 9 38
19234490 2009
26
[Triptolide evaluates DNA methylation level of matrix metalloproteinase 9 gene in human fibrosarcoma HT-1080 cells]. 9 38
19526795 2009
27
Curcumin, demethoxycurcumin and bisdemethoxycurcumin differentially inhibit cancer cell invasion through the down-regulation of MMPs and uPA. 9 38
18495463 2009
28
Mapping proteolytic cancer cell-extracellular matrix interfaces. 9 38
18600304 2009
29
Chondroitin sulfate A regulates fibrosarcoma cell adhesion, motility and migration through JNK and tyrosine kinase signaling pathways. 9 38
19368127 2009
30
TRAIL and Taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma. 9 38
19077262 2008
31
Use of the Rad51 promoter for targeted anti-cancer therapy. 9 38
19106292 2008
32
Secretion of active membrane type 1 matrix metalloproteinase (MMP-14) into extracellular space in microvesicular exosomes. 9 38
18802920 2008
33
Transcription factors as therapeutic targets for diabetes. 9 38
18851698 2008
34
Flavonoid glycosides isolated from Salicornia herbacea inhibit matrix metalloproteinase in HT1080 cells. 9 38
18715546 2008
35
Glucose regulation of insulin gene expression in pancreatic beta-cells. 9 38
18778246 2008
36
Plasminogen activator inhibitor-2, but not cystatin C, inhibits the prometastatic activity of tissue inhibitor of metalloproteinases-1 in the liver. 9 38
18681831 2008
37
Mapping local matrix remodeling induced by a migrating tumor cell using three-dimensional multiple-particle tracking. 9 38
18641063 2008
38
Wdnm1-like, a new adipokine with a role in MMP-2 activation. 9 38
18492766 2008
39
Effects of lentivirus-mediated HIF-1alpha knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells. 9 38
18421307 2008
40
Dimerization of endogenous MT1-MMP is a regulatory step in the activation of the 72-kDa gelatinase MMP-2 on fibroblasts and fibrosarcoma cells. 9 38
18627313 2008
41
Efrapeptin J, a new down-regulator of the molecular chaperone GRP78 from a marine Tolypocladium sp. 9 38
18667784 2008
42
Global and focused transcriptional profiling of small molecule aminopeptidase N inhibitor reveals its mechanism of angiogenesis inhibition. 9 38
18413233 2008
43
Human tissue factor pathway inhibitor-2 induces caspase-mediated apoptosis in a human fibrosarcoma cell line. 9 38
18401718 2008
44
Attenuation of melanoma invasion by a secreted variant of activated leukocyte cell adhesion molecule. 9 38
18483249 2008
45
Fibronectin fragmentation is a feature of periodontal disease sites and diabetic foot and leg wounds and modifies cell behavior. 9 38
18454665 2008
46
Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2. 9 38
18451175 2008
47
A small-molecule furin inhibitor inhibits cancer cell motility and invasiveness. 9 38
18392131 2008
48
Anti-cancer effect of bio-reductive drug beta-lapachon is enhanced by activating NQO1 with heat shock. 9 38
18283592 2008
49
Regulation of hyaluronan and versican deposition by growth factors in fibrosarcoma cell lines. 9 38
17980161 2008
50
Collagen-binding domains of gelatinase A and thrombospondin-derived peptides impede endocytic clearance of active gelatinase A and promote HT1080 fibrosarcoma cell invasion. 9 38
18222489 2008

Variations for Fibrosarcoma

Expression for Fibrosarcoma

Search GEO for disease gene expression data for Fibrosarcoma.

Pathways for Fibrosarcoma

Pathways related to Fibrosarcoma according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.67 TIMP2 TIMP1 SERPINE1 MMP9 MMP2 MMP14
2 12.24 TNF PLAU MMP9 MMP2 FN1
3 12.2 PLAU MMP9 MAF ETV6
4 12.13 TNF MMP9 MMP2 MMP14
5 12.04 TNF MMP9 MMP2 JUN
6
Show member pathways
11.99 TNF MMP9 MMP2 FN1
7 11.97 SERPINE1 MMP9 MMP2 MMP14
8 11.92 TNF MMP9 MMP14 JUN
9 11.91 TNF TIMP1 MMP9 MMP2 FN1
10 11.86 SERPINE1 PLAU MMP14 JUN FN1
11 11.8 TIMP2 TIMP1 MMP9 MMP2
12 11.77 TNF SERPINE1 MMP2 JUN FN1
13 11.72 MMP9 MMP2 JUN
14
Show member pathways
11.7 TNF MAF JUN
15 11.64 MMP9 MMP2 MMP14 JUN
16 11.63 MMP9 MMP2 JUN
17
Show member pathways
11.63 TNF TIMP2 TIMP1 MMP9 MMP2 MMP14
18
Show member pathways
11.61 TNF MMP9 MMP2 JUN
19 11.57 TNF SERPINE1 JUN
20 11.54 PLAU MMP2 JUN
21 11.52 TNF TIMP1 PLAU MMP9 MMP2
22 11.5 TNF MMP2 JUN
23 11.45 PLAU MMP9 JUN
24
Show member pathways
11.45 PLAU MMP9 MMP2 JUN
25 11.34 TNF PLAU MMP9 MMP2 FN1
26 11.24 PLAU MMP9 MMP2 JUN
27 11.13 TIMP2 TIMP1 MMP9
28 11.08 MAFK MAFF MAFB MAFA MAF JUN
29 11.01 TIMP2 TIMP1 SERPINE1 PLAU MMP9 MMP2
30 10.97 TNF TIMP2 TIMP1 NTRK3 JUN FN1
31 10.76 SERPINE1 PLAU

GO Terms for Fibrosarcoma

Cellular components related to Fibrosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.97 TNF TIMP2 TIMP1 SERPINE1 PLAU MMP9
2 collagen-containing extracellular matrix GO:0062023 9.55 TIMP2 SERPINE1 MMP9 MMP2 FN1
3 platelet alpha granule lumen GO:0031093 9.43 TIMP1 SERPINE1 FN1
4 extracellular matrix GO:0031012 9.43 TIMP2 TIMP1 MMP9 MMP2 MMP14 FN1
5 extracellular space GO:0005615 9.36 TNF TIMP2 TIMP1 SERPINE1 PLAU MMP9

Biological processes related to Fibrosarcoma according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.92 TNF NTRK3 MAF FN1 ACTC1
2 negative regulation of apoptotic process GO:0043066 9.9 TIMP1 MMP9 JUN ACTC1
3 positive regulation of cell migration GO:0030335 9.87 PLAU NTRK3 MMP9 MMP14
4 positive regulation of transcription by RNA polymerase II GO:0045944 9.86 TNF SERPINE1 MAFF MAFB MAFA MAF
5 extracellular matrix organization GO:0030198 9.85 TNF SERPINE1 MMP9 FN1
6 cytokine-mediated signaling pathway GO:0019221 9.83 TNF TIMP1 MMP9 MMP2 FN1
7 angiogenesis GO:0001525 9.8 SERPINE1 MMP2 MMP14 JUN FN1
8 circadian rhythm GO:0007623 9.76 SERPINE1 NTRK3 JUN
9 ephrin receptor signaling pathway GO:0048013 9.75 NTRK3 MMP9 MMP2
10 response to hormone GO:0009725 9.69 TIMP2 TIMP1 MMP14
11 response to cytokine GO:0034097 9.67 TIMP2 TIMP1 JUN
12 response to organic substance GO:0010033 9.67 TNF TIMP2 TIMP1 JUN
13 collagen catabolic process GO:0030574 9.63 MMP9 MMP2 MMP14
14 response to muscle stretch GO:0035994 9.61 JUN GPI
15 lens fiber cell differentiation GO:0070306 9.59 NTRK3 MAF
16 regulation of signaling receptor activity GO:0010469 9.56 SERPINE1 PLAU
17 negative regulation of membrane protein ectodomain proteolysis GO:0051045 9.54 TIMP2 TIMP1
18 transcription by RNA polymerase II GO:0006366 9.5 MAFF MAF JUN
19 negative regulation of metallopeptidase activity GO:1905049 9.48 TIMP2 TIMP1
20 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.46 TNF MMP9 MMP2 JUN
21 endodermal cell differentiation GO:0035987 9.26 MMP9 MMP2 MMP14 FN1
22 extracellular matrix disassembly GO:0022617 9.02 TIMP2 TIMP1 MMP9 MMP2 MMP14

Molecular functions related to Fibrosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity GO:0003700 9.8 MAFK MAFF MAFB MAFA MAF JUN
2 sequence-specific DNA binding GO:0043565 9.7 MAFK MAFF MAFB MAFA MAF JUN
3 serine-type endopeptidase activity GO:0004252 9.5 PLAU MMP9 MMP2
4 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.5 MAFK MAFF MAFB MAFA MAF JUN
5 metalloendopeptidase inhibitor activity GO:0008191 9.37 TIMP2 TIMP1
6 protease binding GO:0002020 9.02 TNF TIMP2 TIMP1 SERPINE1 FN1

Sources for Fibrosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....